Blar i NTNU Open på forfatter "Hjortland, Geir Olav"

Viser treff 1-6 av 6

    • Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms 

      Venizelos, Andreas; Sorbye, Halfdan; Elvebakken, Hege; Perren, Aurel; Lothe, Inger Marie Bowitz; Couvelard, Anne; Hjortland, Geir Olav; Sundlöv, Anna; Svensson, Johanna; Garresori, Herish; Kersten, Christian; Hofsli, Eva; Detlefsen, Sönke; Vestermark, Lene W.; Ladekarl, Morten; Tabaksblat, Elizaveta Mitkina; Knappskog, Stian (Peer reviewed; Journal article, 2023)
      High-grade gastroenteropancreatic (HG-GEP) neuroendocrine neoplasms (NENs) are highly aggressive cancers. The molecular etiology of these tumors remains unclear, and the prevalence of pathogenic germline variants in patients ...

    • Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms 

      Elvebakken, Hege; Hjortland, Geir Olav; Garresori, Herish; Andresen, Per Arne; Janssen, Emiel; Vintermyr, Olav Karsten; Lothe, Inger Marie Bowitz; Sorbye, Halfdan (Peer reviewed; Journal article, 2023)
      High-grade gastroenteropancreatic neuroendocrine neoplasms (HG GEP-NEN) typically disseminate early. Treatment of metastatic disease has limited benefit and prognosis is generally discouraging. Data on the clinical impact ...

    • Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway 

      Helland, Åslaug; Russnes, Hege Elisabeth Giercksky; Fagereng, Gro Live; Al-Shibli, Khalid Ibrahim; Andersson, Yvonne; Berg, Thomas; Bjørge, Line; Blix, Egil Støre; Bjerkehagen, Bodil; Brabrand, Sigmund; CAMERON, MARTE; Dalhaug, Astrid; Dietzel, Dalia; Dønnem, Tom; Enerly, Espen; Flobak, Åsmund; Fluge, Sverre; Gilje, Bjørnar; Gjertsen, Bjørn Tore; Grønberg, Bjørn Henning; Grønås, Kari; Guren, Tormod Kyrre; Hamre, Hanne Mari; Haug, Åse; Heinrich, Daniel; Hjortland, Geir Olav; Hovig, Eivind; Hovland, Randi; Iversen, Ann-Charlotte; Janssen, Emiel; Kyte, Jon A; Gythfeldt, Hedda; Lothe, Ragnhild Adelheid; Lund, Jo-Åsmund; Meza, Leonardo Zepeda; Munthe-Kaas, Monica Cheng; Nguyen, Olav Toai Duc; Niehusmann, Pitt; Nilsen, Hilde; Puco, Katarina; Ree, Anne Hansen; Riste, Tonje Bøyum; Semb, Karin; Steinskog, Eli Sihn Samdal; Stensvold, Andreas; Suhrke, Pål; Tennøe, Øyvind Krohn; Tjønnfjord, Geir Erland; Vassbotn, Liv Jorunn; Aas, Eline; Aasebø, Kristine Øverås; Tasken, Kjetil; Smeland, Sigbjørn (Peer reviewed; Journal article, 2022)
      Background Matching treatment based on tumour molecular characteristics has revolutionized the treatment of some cancers and has given hope to many patients. Although personalized cancer care is an old concept, renewed ...

    • The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms 

      Venizelos, Andreas; Elvebakken, Hege; Perren, Aurel; Nikolaienko, Oleksii; Deng, Wei; Lothe, Inger Marie Bowitz; Couvelard, Anne; Hjortland, Geir Olav; Sundlöv, Anna; Svensson, Johanna; Garresori, Herish; Kersten, Christian; Hofsli, Eva; Detlefsen, Sönke; Krogh, Merete; Sørbye, Halfdan; Knappskog, Stian (Peer reviewed; Journal article, 2021)
      High-grade (HG) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are rare but have a very poor prognosis and represent a severely understudied class of tumours. Molecular data for HG GEP-NEN are limited, and ...

    • Mutation Spectrum in Liquid Versus Solid Biopsies From Patients With Advanced astroenteropancreatic Neuroendocrine Carcinoma 

      Knappskog, Stian; Grob, Tobias; Venizelos, Andreas; Amstutz, Ursula; Hjortland, Geir Olav; Lothe, Inger Marie Bowitz; Kersten, Christian; Hofsli, Eva; Sundlöv, Anna; Elvebakken, Hege; Garresori, Herish; Couvelard, Anne; Svensson, Johanna; Sorbye, Halfdan; Perren, Aurel (Peer reviewed; Journal article, 2023)
      Purpose Gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) are rare and have a poor prognosis. Most GEP-NEC are diagnosed with metastatic disease, with only minor biopsies available for molecular diagnostics. We ...

    • Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer in the multicentre, randomised, controlled NeoRes II trial 

      Nilsson, K.; Klevebro, F.; Sunde, B.; Rouvelas, I.; Lindblad, M.; Szabo, E.; Halldestam, I.; Smedh, U.; Wallner, B.; Johansson, J.; Johnsen, Gjermund; Aahlin, Eirik Kjus; Johannessen, Hans Olaf; Alexandersson von Döbeln, von; Hjortland, Geir Olav; Wang, N.; Shang, Y.; Borg, D.; Quaas, A.; Bartella, I.; Bruns, C.; Schröder, W.; Nilsson, M. (Peer reviewed; Journal article, 2023)
      Background The optimal time to surgery (TTS) after neoadjuvant chemoradiotherapy (nCRT) for oesophageal cancer is unknown and has traditionally been 4-6 weeks in clinical practice. Observational studies have suggested ...